From: HDAC inhibitors in experimental liver and kidney fibrosis
Name | Alternative names | HDACs inhibited | # of clinical trials | Disease |
---|---|---|---|---|
Vorinostat | N1-hydroxy-N8-phenyl-octanediamide, SAHA, Suberoylanilide Hydroxamic Acid, Zolinza | Class I and II | 72 | Breast Cancer; Ovarian, Fallopian Tube, or Peritoneal Cancer; Prostate Cancer; Soft Tissue Sarcoma; Non-Small Cell Lung Cancer; Solid Tumors with/without HIV infection; Gastric cancer; Multiple Myeloma; Multiple Lymphoid Malignancies, such as Leukemia, Mantle Cell Lymphoma; Large B-Cell Lymphoma; T-Cell Lymphoma; Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, Myelodysplastic Syndromes or Myeloproliferative Disorders; Adenoid Cystic Carcinoma; Head and Neck Cancer; Brain Metastasis; Neuroblastoma; Glioma; Glioblastoma Multiforme; Embryonal Tumors of the Central Nervous System; Metastatic Melanoma of the Eye; Graft-Host Disease; Renal Cell Carcinoma |
Panobinostat | LBN-589; LBH589; NVP-LBH589 | Class I, II and IV | 23 | Myelodysplastic Syndrome; Metastatic Gastric Cancer; Breast Cancer; B-Cell Lymphoma; Leukemia; Graft-Host Disease; Renal Cell Carcinoma; Hodgkin’s Lymphoma; Lung Cancer; Prostate Cancer; Hepatocellular Carcinoma; T-Cell Lymphoma; Chordoma |
Valproic acid | Dipropylacetic acid, VPA, myproic acid, Depakene | Class I | 12 | Sarcoma; Myelodysplastic Syndrome; Leukemia; Lymphoma; Gliomas; Cervical Cancer; Ovarian cancer |
Entinostat | SNDX-275; MS-27-275, MS-275 | HDAC1,3 | 6 | Leukemia; Renal Cell Carcinoma; Resected Stage I Non-Small Cell Lung Cancer |
Belinostat | PXD101; PX105684 | Class I, II and IV | 2 | Small Cell Lung Carcinoma; Lymphomas |
CUDC-101 | 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide | multitargeted HDAC, EGFR and HER2 inhibitor | 2 | Head and Neck Cancers |